Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Pharmaceuticals market research, reports and industry analysis

mail

Contact us for professional industry advice

Email us or call

+44(0)20 7936 6830
mail

for FREE research alerts
to your inbox

120 Item(s)

Page 1 of 12

  1. Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

    By: GBI Research
    , Published: Jun-2016
    , Product code: GBIHC397MR
    Diabetes is a common long-term condition that can lead to a range of disparate and serious complications. It is a lifelong, multi-systemic condition that affects a number of integral organs. Diabetes has a rapidly increasing prevalence – it currently affects 10% of adults globally, and is estimated to become the seventh-leading cause of death by 2030.
    $6,995.00

  2. Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies

    By: GBI Research
    , Published: Jun-2016
    , Product code: GBIHC394MR
    Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow, and include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating that lymphomas are more prevalent than leukemia or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.
    $6,995.00

  3. Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth

    By: GBI Research
    , Published: May-2016
    , Product code: GBIHC390MR
    Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition.For the past decades, the majority of the dermatology market has remained saturated with established products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.
    $4,995.00

  4. Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

    By: GBI Research
    , Published: May-2016
    , Product code: GBIHC408MR
    Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.
    $4,995.00

  5. Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market

    By: GBI Research
    , Published: Apr-2016
    , Product code: GBIHC407MR
    Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating lymphomas are more prevalent than leukemias or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.
    $4,995.00

  6. Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

    By: GBI Research
    , Published: Apr-2016
    , Product code: GBIHC406MR
    Viruses are infectious particles comprising a nucleic acid core – consisting of either DNA or RNA – and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Viruses replicate by exploiting the resources of their host cells, usually to the detriment of the host. As viral pathogens are exceptionally diverse, the morbidity associated with viral infections varies significantly depending on the virus in question. This report covers all viral infections, although particular focus is given to four key indications within this disease cluster: Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and influenza. The global viral infections market was valued at $74.0 billion in 2014, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8%, reaching $117.6 billion in 2021. Key drivers of this growth will be the expanding treatment population and uptake of recently approved highly priced antiviral agents, as well as promising late-stage candidates that are expected to be priced highly.
    $4,995.00

  7. Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms

    By: GBI Research
    , Published: Apr-2016
    , Product code: GBIHC393MR
    Schizophrenia is a severe mental disorder that is characterized by abnormal social behavior and failure to recognize what is real; its symptoms are broadly divided into positive, negative and cognitive. The treatment of schizophrenia is multi-factorial and includes medical, psychological and psychosocial inputs. Antipsychotic medication is the main pharmacological agent used, along with counselling, job training, and social rehabilitation. Both typical and atypical antipsychotics are used, and the choice of medication is usually left to the discretion of the treating physician. Clozapine, which is an atypical antipsychotic that binds to serotonin and dopamine receptors, is often given to patients who do not improve with other antipsychotics.
    $6,995.00

  8. Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics

    By: GBI Research
    , Published: Apr-2016
    , Product code: GBIHC405MR
    In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.
    $4,995.00

  9. Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs

    By: GBI Research
    , Published: Mar-2016
    , Product code: GBIHC396MR
    Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients. As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.
    $6,995.00

  10. Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns

    By: GBI Research
    , Published: Mar-2016
    , Product code: GBIHC403MR
    Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.
    $4,995.00

120 Item(s)

Page 1 of 12